Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies

Authors: Mease, Philip J ^*, Helliwell, Philip S, Gladman, Dafna D, Poddubnyy, Denis, Baraliakos, Xenofon, Chakravarty, Soumya D, Kollmeier, Alexa P, Hsia, Elizabeth C, Xu, Xie L, Sheng, Shihong, Agarwal, Prasheen, Zhou, Bei, Sweet, Kristen, Shawi, May, Karyekar, Chetan S, Deodhar, Atul, van der Heijde, Désirée

Source: In The Lancet Rheumatology October 2021 3(10):e715-e723

Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis

Authors: McInnes, Iain B., Rahman, Proton, Gottlieb, Alice B., Hsia, Elizabeth C., Kollmeier, Alexa P., Chakravarty, Soumya D., Xu, Xie L., Subramanian, Ramanand A., Agarwal, Prasheen, Sheng, Shihong, Jiang, Yusang, Zhou, Bei, Zhuang, Yanli, Heijde, Désirée, Mease, Philip J.

Source: Arthritis & rheumatology. 73(4):604-616

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100139194414.0x000001&indx=1&recIds=ETOCvdc_100139194414.0x000001

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

Authors: Mease, Philip J ^*, Rahman, Proton, Gottlieb, Alice B, Kollmeier, Alexa P, Hsia, Elizabeth C, Xu, Xie L, Sheng, Shihong, Agarwal, Prasheen, Zhou, Bei, Zhuang, Yanli, van der Heijde, Désirée, McInnes, Iain B

Source: In The Lancet 4-10 April 2020 395(10230):1126-1136

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

Authors: Deodhar, Atul ^*, Helliwell, Philip S, Boehncke, Wolf-Henning, Kollmeier, Alexa P, Hsia, Elizabeth C, Subramanian, Ramanand A, Xu, Xie L, Sheng, Shihong, Agarwal, Prasheen, Zhou, Bei, Zhuang, Yanli, Ritchlin, Christopher T

Source: In The Lancet 4-10 April 2020 395(10230):1115-1125

Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study

Authors: Aletaha, Daniel, Bingham, Clifton O, III, Tanaka, Yoshiya, Agarwal, Prasheen, Kurrasch, Regina, Tak, Paul P, Popik, Sharon

Source: In The Lancet 25-31 March 2017 389(10075):1206-1217

Long-term safety study of infliximab in moderate-to-severe chronic obstructive pulmonary disease

Authors: Rennard, Stephen I., Flavin, Susan K., Agarwal, Prasheen K., Lo, Kim Hung, Barnathan, Elliot S.

Source: In Respiratory Medicine March 2013 107(3):424-432

The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.

Authors: Curtis, Jeffrey R., McInnes, Iain B., Rahman, Proton, Gladman, Dafna D., Peterson, Steven, Agarwal, Prasheen, Yang, Feifei, Kollmeier, Alexa P., Hsia, Elizabeth C., Shiff, Natalie J., Zhou, Bei, Han, Chenglong, Shawi, May, Tillett, William, Mease, Philip J.

Source: Advances in Therapy; Oct2022, Vol. 39 Issue 10, p4613-4631, 19p

Subject Terms: BIOTHERAPY, PSORIATIC arthritis, RESEARCH, RESEARCH methodology, MONOCLONAL antibodies, EVALUATION research, TREATMENT effectiveness, SEVERITY of illness index, COMPARATIVE studies, RANDOMIZED controlled trials, BLIND experiment, QUESTIONNAIRES

The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.

Authors: Curtis, Jeffrey R., McInnes, Iain B., Rahman, Proton, Gladman, Dafna D., Yang, Feifei, Peterson, Steven, Agarwal, Prasheen, Kollmeier, Alexa P., Hsia, Elizabeth C., Han, Chenglong, Shiff, Natalie J., Shawi, May, Tillett, William, Mease, Philip J.

Source: Advances in Therapy; Oct2022, Vol. 39 Issue 10, p4632-4644, 13p

Subject Terms: BIOTHERAPY, PSORIATIC arthritis, RESEARCH, PAIN, MONOCLONAL antibodies, EVALUATION research, COMPARATIVE studies, RANDOMIZED controlled trials, QUALITY of life, FATIGUE (Physiology)

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

Authors: Guilhot, Francois ^*, Apperley, Jane, Kim, Dong-Wook, Bullorsky, Eduardo O., Baccarani, Michele, Roboz, Gail J., Amadori, Sergio, de Souza, Carmino A., Lipton, Jeffrey H., Hochhaus, Andreas, Heim, Dominik, Larson, Richard A., Branford, Susan, Muller, Martin C., Agarwal, Prasheen, Gollerkeri, Ashwin, Talpaz, Moshe

Source: In Blood 15 May 2007 109(10):4143-4150

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

Authors: Cortes, Jorge ^*, Rousselot, Philippe, Kim, Dong-Wook, Ritchie, Ellen, Hamerschlak, Nelson, Coutre, Steven, Hochhaus, Andreas, Guilhot, Francois, Saglio, Giuseppe, Apperley, Jane, Ottmann, Oliver, Shah, Neil, Erben, Philipp, Branford, Susan, Agarwal, Prasheen, Gollerkeri, Ashwin, Baccarani, Michele

Source: In Blood 15 April 2007 109(8):3207-3213

27038 Efficacy of guselkumab using composite endpoints in patients with active psoriatic arthritis: Domain-specific efficacy from DISCOVER-1 and DISCOVER-2 phase 3 trials

Authors: Coates, Laura C., Ritchlin, Christopher T., Gossec, Laure, Helliwell, Philip S., Rahman, Proton, Kollmeier, Alexa P., Karyekar, Chetan, Sheng, Shihong, Agarwal, Prasheen, Mease, Philip J.

Source: Journal of the American Academy of Dermatology. 85(3):AB127-AB127

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100134187671.0x000001&indx=1&recIds=ETOCvdc_100134187671.0x000001

27847 Guselkumab (GUS) efficACy in TNF-inhibitor-experienced and TNF-inhibitor-naïve patients with active psoriatic arthritis (PsA): Results of a phase 3, randomized, controlled study

Authors: Ritchlin, Christopher T., Deodhar, Atul, Boehncke, Wolf-Henning, Soriano, Enrique R., Kollmeier, Alexa P., Shawi, May, Yang, Ya-Wen, Sheng, Shihong, Agarwal, Prasheen, Helliwell, Philip S.

Source: Journal of the American Academy of Dermatology. 85(3):AB163-AB163

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100134186005.0x000001&indx=1&recIds=ETOCvdc_100134186005.0x000001

15281 Effects of guselkumab on articular components of American College of Rheumatology score and skin responses in patients with active psoriatic arthritis: Results from the phase 3 DISCOVER-2 study

Authors: Gottlieb, Alice B., Mease, Philip J., Merola, Joseph F., Kollmeier, Alexa P., Hsia, Elizabeth C., Xu, Xie L., Agarwal, Prasheen, van der Heijde, Désirée, McInnes, Iain B., Boehncke, Wolf-Henning

Source: Journal of the American Academy of Dermatology. 83(6):AB145-AB145

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100115040945.0x000001&indx=1&recIds=ETOCvdc_100115040945.0x000001

Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.

Authors: Rahman, Proton, Ritchlin, Christopher T., Helliwell, Philip S., Boehncke, Wolf-Henning, Mease, Philip J., Gottlieb, Alice B., Kafka, Shelly, Kollmeier, Alexa P., Hsia, Elizabeth C., Xu, Xie L., Shawi, May, Shihong Sheng, Agarwal, Prasheen, Bei Zhou, Ramachandran, Paraneedharan, Yanli Zhuang, McInnes, Iain B., Sheng, Shihong, Zhou, Bei, Zhuang, Yanli

Source: Journal of Rheumatology; Dec2021, Vol. 48 Issue 12, p1816-1823, 9p

Subject Terms: PSORIATIC arthritis, BIOLOGICALS, DRUG side effects, PSORIASIS, RESEARCH, RESEARCH methodology, MONOCLONAL antibodies, EVALUATION research, TREATMENT effectiveness, SEVERITY of illness index, COMPARATIVE studies, RANDOMIZED controlled trials, BLIND experiment, STATISTICAL sampling

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.

Authors: McGonagle, Dennis, McInnes, Iain B, Deodhar, Atul, Schett, Georg, Shawi, May, Kafka, Shelly, Karyekar, Chetan S, Kollmeier, Alexa P, Hsia, Elizabeth C, Xu, Xie L, Sheng, Shihong, Agarwal, Prasheen, Zhou, Bei, Ritchlin, Christopher T, Rahman, Proton, Mease, Philip J

Source: Rheumatology; Nov2021, Vol. 60 Issue 11, p5337-5350, 14p

Subject Terms: THERAPEUTIC use of monoclonal antibodies, TENDON injuries, INTERLEUKINS, PSORIATIC arthritis, STATISTICS, MONOCLONAL antibodies, PHYSICAL fitness, TREATMENT effectiveness, RANDOMIZED controlled trials, DATA analysis, STATISTICAL sampling, CHEMICAL inhibitors, ADULTS

Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE).

Authors: Aletaha, Daniel, Bingham, Clifton O., Karpouzas, George Athanasios, Tsutomu Takeuchi, Thorne, Carter, Bili, Androniki, Agarwal, Prasheen, Hsu, Benjamin, Rao, Ravi, Brown, Kurt, Yoshiya Tanaka

Source: RMD Open; 2/15/2021, Vol. 7 Issue 1, p1-11, 11p

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced

Authors: Ritchlin, Christopher T., Helliwell, Philip S., Boehncke, Wolf-Henning, Soriano, Enrique R., Hsia, Elizabeth C., Kollmeier, Alexa P., Chakravarty, Soumya D., Zazzetti, Federico, Subramanian, Ramanand A., Xu, Xie L., Zuraw, Qing C., Shihong Sheng, Yusang Jiang, Agarwal, Prasheen, Bei Zhou, Yanli Zhuang, Shawi, May, Karyekar, Chetan S., Deodhar, Atul

Source: RMD Open; 2/15/2021, Vol. 7 Issue 1, p1-11, 11p

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.